nach oben

Erschienen in:

26.02.2019 | Original Article

Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device

verfasst von: Yaoguang Zhang, Peng Zhang, Xiaojun Tian, Guoqing Chen, Yan Li, Yong Zhang, Zhihui Xu, Zhongqing Wei, Wei Zhang, Lulin Ma, Benkang Shi, Limin Liao, Jianye Wang

Erschienen in: World Journal of Urology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The efficacy and safety of a novel remotely programmed BetterStim sacral neuromodulation (SNM) system was evaluated in patients with refractory overactive bladder (OAB) in a prospective, controlled, multicenter trial.

Methods

A total of 84 patients referred for SNM therapy from October 2015 to January 2018 were studied. Of the patients who qualified for implantation, 37 and 33 were randomly assigned to treatment and control groups, respectively. Patients in the treatment group underwent stimulation upon implantation, while stimulation was delayed in the control group for 3 months. Follow-up visits, consisting of voiding diary outcome, questionnaires regarding overactive bladder symptom score (OABSS) and quality of life were conducted at 1, 3, and 6-month post-implantation.

Results

Compared with the control group, subjects in the treatment group exhibited statistically significant improvement in OAB symptoms at 3 months. The overall success rate was achieved in 72% of the treatment group, compared with 12% of the control group at 3 months. At 6 months, there were no significant differences in key voiding diary variables between the two groups. Further, this study demonstrated sustained improvement in urinary symptom interference in OAB patients. In addition, nearly all patients expressed great satisfaction with the remote-programming methods. No serious adverse events occurred, and device-related adverse events rate was 12.86%.

Conclusion

This clinical study demonstrates subjective and objective success of the BetterStim SNM system. Importantly, our data suggest that remote programming can be safely used as a viable option for the conventional programming with a high degree of patient satisfaction.

White N, Iglesia CB (2016) Overactive bladder. Obstet Gynecol Clin North Am 43(1):59–68. https://doi.org/10.1016/j.ogc.2015.10.002 CrossRefPubMed

Eapen RS, Radomski SB (2016) Review of the epidemiology of overactive bladder. Res Rep Urol 8:71–76. https://doi.org/10.2147/RRU.S102441 CrossRefPubMedPubMedCentral

Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20(6):327–336. https://doi.org/10.1007/s00345-002-0301-4 CrossRefPubMed

Ruffion A, Castro-Diaz D, Patel H, Khalaf K, Onyenwenyi A, Globe D, Lereun C, Teneishvili M, Edwards M (2013) Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder. Neuroepidemiology 41(3–4):146–155. https://doi.org/10.1159/000353274 CrossRefPubMed

Wang Y, Xu K, Hu H, Zhang X, Wang X, Na Y, Kang X (2011) Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China. Neurourol Urodyn 30(8):1448–1455. https://doi.org/10.1002/nau.21072 CrossRefPubMed

Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, Comiter C, Culkin D, Bennett J, Zylstra S, Berg KC, Kan F, Irwin CP (2015) Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn 34(3):224–230. https://doi.org/10.1002/nau.22544 CrossRefPubMed

Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT, Myers DL, Zyczynski HM, Vasavada S, Nolen TL, Wallace D, Meikle SF (2016) Onabotulinumtoxin A vs sacral neuromodulation on refractory urgency urinary incontinence in Women: a randomized clinical trial. JAMA 316(13):1366–1374. https://doi.org/10.1001/jama.2016.14617 CrossRefPubMedPubMedCentral

Tang H, Chen J, Wang Y, Yu T, Guo C, Liao X (2014) Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial. Urol J 11(4):1800–1805PubMed

Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE, Bird ET, Comiter C, Culkin D, Zylstra S, Kan F, Berg KC (2018) Five-year followup results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. J Urol 199(1):229–236. https://doi.org/10.1016/j.juro.2017.07.010 CrossRefPubMed

10.

Braun PM, Bohler G (2006) Results of sacral nerve modulation for treatment of overactive bladder. Urologe A 45(7):835–840. https://doi.org/10.1007/s00120-006-1085-8 CrossRefPubMed

11.

Matzel KE, Stadelmaier U, Hohenfellner M, Gall FP (1995) Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence. Lancet 346(8983):1124–1127CrossRef

12.

Blok B, Van Kerrebroeck P, de Wachter S, Ruffion A, Van der Aa F, Jairam R, Perrouin-Verbe M, Elneil S (2018) Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder. Neurourol Urodyn 37(S2):S9–S16. https://doi.org/10.1002/nau.23465 CrossRefPubMed

13.

Elterman DS (2018) The novel axonics (R) rechargeable sacral neuromodulation system: procedural and technical impressions from an initial North American experience. Neurourol Urodyn 37(S2):S1–S8. https://doi.org/10.1002/nau.23482 CrossRefPubMed

14.

Chen Y, Hao H, Chen H, Tian Y, Li L (2014) The study on a real-time remote monitoring system for Parkinson’s disease patients with deep brain stimulators. Conf Proc IEEE Eng Med Biol Soc 2014:1358–1361. https://doi.org/10.1109/EMBC.2014.6943851 CrossRefPubMed

15.

Hwa K, Wren SM (2013) Telehealth follow-up in lieu of postoperative clinic visit for ambulatory surgery: results of a pilot program. JAMA Surg 148(9):823–827. https://doi.org/10.1001/jamasurg.2013.2672 CrossRefPubMed

16.

Chen Y, Hao H, Chen H, Li L (2015) The study on a telemedicine interaction mode for Deep Brain Stimulation postoperative follow-up. Conf Proc IEEE Eng Med Biol Soc 2015:186–189. https://doi.org/10.1109/EMBC.2015.7318331 CrossRefPubMed

17.

Zhang C, Li D, Zeljic K, Tan H, Ning Y, Sun B (2016) A remote and wireless deep brain stimulation programming system. Neuromodulation 19(4):437–439. https://doi.org/10.1111/ner.12448 CrossRefPubMed

18.

Schulz KF, Altman DG, Moher D, Group C (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med 8:18. https://doi.org/10.1186/1741-7015-8-18 CrossRefPubMedPubMedCentral

19.

Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D (2013) Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther 35(11):1744–1751. https://doi.org/10.1016/j.clinthera.2013.08.017 CrossRefPubMed

20.

Matzel KE, Chartier-Kastler E, Knowles CH, Lehur PA, Munoz-Duyos A, Ratto C, Rydningen MB, Sorensen M, van Kerrebroeck P, de Wachter S (2017) Sacral neuromodulation: standardized electrode placement technique. Neuromodulation 20(8):816–824. https://doi.org/10.1111/ner.12695 CrossRefPubMed

21.

Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11(6):563–574CrossRef

22.

Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, Comiter C, Culkin D, Bennett J, Zylstra S, Kan F, Thiery E (2016) Three-year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. Urology 94:57–63. https://doi.org/10.1016/j.urology.2016.04.024 CrossRefPubMed

23.

Noblett K, Berg KC, Kan F, Siegel S (2018) Baseline symptom severity and therapeutic success in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients. Neurourol Urodyn 37(5):1667–1671. https://doi.org/10.1002/nau.23422 CrossRefPubMed

24.

van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama a Nijholt AA, Siegel S, Jonas U, Fowler CJ, Fall M, Gajewski JB, Hassouna MM, Cappellano F, Elhilali MM, Milam DF, Das AK, Dijkema HE, van den Hombergh U (2007) Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 178(5):2029–2034. https://doi.org/10.1016/j.juro.2007.07.032 CrossRefPubMed

25.

Noblett K, Benson K, Kreder K (2017) Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients. Neurourol Urodyn 36(4):1136–1139. https://doi.org/10.1002/nau.23076 CrossRefPubMed

26.

McElveen JT Jr, Blackburn EL, Green JD Jr, McLear PW, Thimsen DJ, Wilson BS (2010) Remote programming of cochlear implants: a telecommunications model. Otol Neurotol 31(7):1035–1040. https://doi.org/10.1097/MAO.0b013e3181d35d87 CrossRefPubMed

Titel: Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device
verfasst von: Yaoguang Zhang
Peng Zhang
Xiaojun Tian
Guoqing Chen
Yan Li
Yong Zhang
Zhihui Xu
Zhongqing Wei
Wei Zhang
Lulin Ma
Benkang Shi
Limin Liao
Jianye Wang
Publikationsdatum: 26.02.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 11/2019
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-02698-7

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2019

Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience

Medical dissolution therapy for the treatment of uric acid nephrolithiasis

Robotic radical nephroureterectomy and segmental ureterectomy for upper tract urothelial carcinoma: a multi-institutional experience

Consultation on UTUC, Stockholm 2018 aspects of risk stratification: long-term results and follow-up

Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio